Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[5]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[5]. - Basic earnings per share for the period were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[6]. - The company achieved a pre-tax profit of RMB 63.43 million, recovering from a loss of RMB 61.19 million in the same period last year[3]. - The company’s comprehensive income attributable to shareholders was RMB 68.33 million, compared to a loss of RMB 36.68 million in the same period last year[3]. - Operating revenue increased to RMB 522,827,706, a 92.74% increase compared to RMB 271,259,675 in the same period last year[51]. - The total profit for the period was RMB 63,432,798, a significant recovery from a loss of RMB 61,189,485 in the same period last year[127]. - The company reported a net loss of RMB 36,020,882 for the six months ended June 30, 2022, which highlights the financial challenges faced in that period[136]. Assets and Liabilities - The company's total assets reached RMB 3.03 billion, up 1.85% from RMB 2.98 billion at the end of the previous year[4]. - Total liabilities stood at RMB 716.04 million, slightly down from RMB 722.99 million in the previous year[4]. - Cash and cash equivalents as of June 30, 2023, totaled RMB 1,231,128,499, significantly exceeding the outstanding loan balance[54]. - The company has no asset pledges as of June 30, 2023[57]. - The total assets of Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. are RMB 565,336,994, with a net profit of RMB 14,787,447[64]. - The company's total liabilities decreased slightly to RMB 716,037,743 from RMB 722,985,917, indicating a reduction of about 0.13%[122]. - The company’s total equity increased to RMB 2,314,975,432 from RMB 2,253,021,355, reflecting a growth of approximately 2.75%[122]. Research and Development - Research and development expenses accounted for 22.68% of revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[6]. - The company has invested a total of approximately ¥118.59 million in R&D, representing a 10.99% increase compared to the previous period[30]. - The company is focusing its R&D on innovative drugs for skin diseases, tumors, and autoimmune diseases, with a strategic emphasis on photodynamic drugs and antibody-drug conjugates[48]. - The company has established a gene engineering technology platform, focusing on the development of monoclonal antibodies and antibody-drug conjugates (ADC), which are key areas for future commercialization[20]. - The company’s research and development strategy emphasizes addressing unmet clinical needs and achieving differentiated competition through innovative drug development[19]. - The company is conducting Phase I clinical trials for multiple antibody-drug conjugates (ADCs) targeting various cancers, including DM1 for CD30, SN38 for Trop2, and BB05 for Her2, with the first patient enrolled in January 2023 for the BB05 project[21]. - The company has established a nanotechnology platform, with the liposomal formulation里葆多® launched in 2009, and has received acceptance for consistency evaluation of its doxorubicin liposome injection[25]. Market and Industry Trends - The global pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 3-6% from 2023 to 2027, reaching approximately $1.9 trillion[10]. - The Chinese pharmaceutical market's CAGR from 2016 to 2020 was 3.70%, with a total market size of $221.4 billion in 2020, projected to reach $349.8 billion by 2025 and $457.4 billion by 2030[10]. - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion to RMB 471.8 billion from 2017 to 2021, with a CAGR of 11.95%[11]. - The incidence of malignant tumors remains a significant health threat, with lung cancer being the most prevalent, accounting for a substantial portion of new cases in China[14]. - The global oncology spending is projected to reach $370 billion by 2027, driven by the introduction of new drugs and biosimilars[14]. Risks and Challenges - The company faces risks related to new drug development, which can take over ten years and involve significant costs and uncertainties[43]. - The company has a risk of core technical personnel turnover, which could impact its competitive advantage and stability in R&D and production services[44]. - The company may face drug price reduction risks due to government policies and market competition, which could negatively impact revenue[47]. - The company is exposed to potential foreign exchange risks, although most transactions occur in the domestic market[46]. Corporate Governance and Shareholder Matters - The company has established a three-year dividend return plan for shareholders from 2023 to 2025[71]. - The company has completed the nomination of candidates for the eighth board of directors and the supervisory board, with elections held on May 30, 2023[72]. - The company has recognized new core technical personnel, including Li Xiaowen, Yu Daiqing, Chen Yu, and Yang Tong, based on their contributions to R&D and business development[73]. - The company has a restricted stock incentive plan that includes a total of 38 million shares, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[75]. - The company has not reported any changes in controlling shareholders or actual controllers during the reporting period[119]. Environmental and Social Responsibility - The company has established a comprehensive environmental management system and adheres to national and local standards for pollutant emissions, with no violations reported during the reporting period[88][90]. - The company has implemented strict measures for wastewater treatment, ensuring compliance with the Biopharmaceutical Industry Pollutant Discharge Standards[89]. - The company is committed to sustainable development and has set five-year environmental goals based on 2020 levels to enhance its environmental management[90]. - The company has implemented carbon reduction measures, achieving a reduction of 117.651 tons of CO2 equivalent emissions[91]. Financial Management - The total amount raised from the IPO was RMB 1,074 million, with a net amount of RMB 974.32 million after deducting issuance costs[98]. - The company approved the use of RMB 96 million of excess raised funds for replenishing working capital[100]. - The company plans to manage temporarily idle raised funds, with a maximum of RMB 350 million allocated for cash management in safe and liquid investment products[101]. - The company’s financial strategies are focused on enhancing profitability and safeguarding shareholder interests[102].

Financial Performance - Revenue for the first quarter reached RMB 189,147,552, representing a year-on-year increase of 34.33%[2] - Net profit attributable to shareholders was RMB 8,787,158, an increase of 78.39% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 2,349,656, reflecting a significant increase of 252.85%[2] - Operating profit for Q1 2023 was 3,481,590, a significant recovery from a loss of 1,492,333 in Q1 2022[11] - Net profit for Q1 2023 was 8,794,123, compared to 4,810,020 in Q1 2022, reflecting a year-over-year increase of 83.5%[11] - The company reported a basic and diluted earnings per share of 0.01 for Q1 2023, compared to 0.00 in Q1 2022[11] Research and Development - Research and development expenses totaled RMB 54,511,436, accounting for 28.82% of revenue, a decrease of 6.49 percentage points from the previous year[2] - Research and development expenses increased to 54,123,028, up from 48,439,435, indicating a focus on innovation[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,850,342,292, a decrease of 4.22% from the end of the previous year[2] - Total current assets decreased to 1,863,871,518 from 2,069,188,785, a decline of 9.9%[9] - Total liabilities decreased from 722,985,917 to 588,372,864, a reduction of 18.6%[10] - Cash and cash equivalents decreased from 1,289,302,664 to 888,009,829, a decline of 31.1%[9] - Total assets decreased from 2,976,007,272 to 2,850,342,292, a decline of 4.2%[10] Cash Flow - The net cash flow from operating activities was negative at RMB -160,260,214, primarily due to payments made to suppliers from the previous year[4] - In Q1 2023, cash inflow from operating activities was 162,901,241, down 18.9% from 200,904,381 in Q1 2022[13] - Cash outflow for purchasing goods and services increased significantly to 228,636,546, compared to 112,337,883 in the same period last year, representing a 103.6% increase[13] - Net cash flow from operating activities was -160,260,214, worsening from -17,207,380 in Q1 2022[13] - Cash inflow from investment activities totaled 1,055,510,659, slightly up from 1,054,566,056 in Q1 2022[13] - Cash outflow for investment activities rose to 1,291,246,012, compared to 1,094,314,314 in the previous year, marking an 18% increase[13] - Net cash flow from investment activities was -235,735,353, compared to -39,748,258 in Q1 2022[13] - Cash flow from financing activities resulted in an outflow of 5,251,044, up from 2,161,665 in Q1 2022[13] - The net increase in cash and cash equivalents was -401,292,835, compared to -59,130,975 in the same quarter last year[13] - The ending balance of cash and cash equivalents was 888,009,829, down from 1,149,749,936 in Q1 2022[13] Shareholder Information - The company reported a total of 21,986 shareholders at the end of the reporting period[6] Government Subsidies - The company received government subsidies amounting to RMB 3,216,857, which are closely related to its normal business operations[3] Product and Market Development - Major products sales improved during the reporting period, contributing to the overall revenue growth[4] - The company has not reported any new products or technologies, market expansions, or mergers in this quarter[14]

Financial Performance - Total revenue for 2022 was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[7] - Profit before tax for 2022 was RMB 132,294,000, down 38.8% from RMB 215,921,000 in 2021[7] - Net profit attributable to shareholders for 2022 was RMB 137,997,000, a decrease of 35.4% compared to RMB 213,296,000 in 2021[7] - The basic and diluted earnings per share attributable to shareholders for 2022 was RMB 0.1340, down from RMB 0.2049 in 2021[7] - The company's net profit for 2022 was approximately RMB 137,272 thousand, a decline of about 35% from RMB 212,381 thousand in 2021, resulting in a net profit margin of 13% compared to 19% in the previous year[79] - The cost of goods sold for 2022 was RMB 84,062 thousand, up from RMB 80,899 thousand in 2021, with the cost-to-revenue ratio increasing from 7% to 8%[68] - Sales expenses for 2022 were RMB 554,631 thousand, an 8% decrease from RMB 599,697 thousand in 2021, while the ratio of sales expenses to revenue increased from 53% to 54%[69] - Research and development expenses for 2022 amounted to RMB 226,851 thousand, a 1% increase from RMB 224,387 thousand in 2021, while total R&D investment decreased by 6% to RMB 233,659 thousand[70] - Other income for 2022 was RMB 10,465 thousand, a decrease of 52% from RMB 21,687 thousand in 2021, attributed to a reduction in government subsidies[75] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 2,976,007,000, an increase of 7% from RMB 2,781,172,000 in 2021[9] - Total liabilities as of December 31, 2022, were RMB 722,986,000, an increase of 22.2% from RMB 591,582,000 in 2021[9] - As of December 31, 2022, the company's long-term equity investments had a net book value of RMB 305,767 thousand, with an investment loss of approximately RMB 19,800 thousand recorded during the reporting period[81] - As of December 31, 2022, the company had cash and cash equivalents of approximately RMB 1,289,303 thousand, an increase from RMB 1,208,881 thousand at the end of 2021[94] Research and Development - The company aims to become an innovator and leader in the biopharmaceutical industry, focusing on effective treatment solutions[12] - The company emphasizes the importance of new drug development as a reflection of value creation in the pharmaceutical industry[12] - The company plans to continue exploring clinical treatment gaps and providing more effective therapeutic options[12] - The company has a strong commitment to addressing unmet clinical needs through innovative drug development[16] - The company has established a gene engineering technology platform, focusing on developing cytokine, fusion protein, monoclonal antibody, and antibody-drug conjugate products to meet unmet clinical needs[174] - The company has established a nanotechnology platform for drug development, focusing on liposomal formulations to enhance drug solubility and bioavailability, addressing significant technical barriers in the industry[177] - The company has maintained a balance between innovative and generic drug development, ensuring that its projects meet clinical needs and demonstrate unique therapeutic effects[171] Clinical Trials and Product Development - The company is a leader in the development of photodynamic drugs, with ongoing research targeting skin diseases, tumors, and precancerous lesions[16] - The product ALA® has been successfully commercialized and is now the preferred clinical drug for treating condyloma acuminatum, with multiple new indications being explored[17] - Clinical research for ALA® in treating cervical precancerous lesions has shown significant progress, with a new optimized Phase II clinical study plan developed[20] - The company is conducting Phase II clinical trials for ALA® in treating moderate to severe acne, focusing on pain-free treatment options[20] - The company has initiated Phase II clinical trials for ALA® in treating glioblastoma, confirming its potential clinical benefits[20] - The product Revamed® (Heimofen) is the world's first photodynamic drug for treating capillary malformations, with ongoing Phase II clinical trials in the U.S.[22] - The company's first ADC drug, targeting CD30, completed Phase I clinical trials and is now undergoing an expansion Phase I trial for relapsed/refractory CD30-positive peripheral T-cell lymphoma[26] - The ADC drug targeting Trop2 for triple-negative breast cancer, bladder cancer, and gastric cancer is currently in Phase I clinical research, aiming to achieve similar clinical results as the original drug[28] - The ADC drug targeting HER2 for metastatic breast cancer and gastric cancer has initiated Phase I clinical research, with the first subject enrolled in January 2023[29] - The company has developed a new linker-drug platform (BB05 platform) to support the development of Me-better or innovative ADC drugs[28] - The Parkinson's disease controlled-release drug project (WD-1603) completed Phase II clinical research and is expected to enter Phase III trials soon, utilizing the UGi-Pump® technology[30] - The small molecule JAK1 selective inhibitor for rheumatoid arthritis is currently in Phase I clinical research, with additional projects for atopic dermatitis and ulcerative colitis in Phase II[31] - The company has received approval for a topical JAK1 selective inhibitor for atopic dermatitis to commence Phase I clinical trials[31] Market and Industry Trends - The global pharmaceutical market is projected to exceed USD 1.1 trillion by 2024, with a compound annual growth rate of 3-6% expected until 2026[59] - By 2025, the Chinese pharmaceutical market is estimated to reach RMB 2.1 trillion, with the biopharmaceutical market expected to account for 48%[59] - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a CAGR of 11.95%[153] - The global oncology drug expenditure is projected to reach $370 billion by 2027, driven by the acceleration of new drug launches and biosimilars[157] - In China, approximately 2.2 million new cancer cases are reported annually, with a mortality rate of 1.6 million, indicating a 20% annual increase in incidence and mortality over the past two decades[157] Corporate Governance and Strategy - The company emphasizes the importance of balancing innovative drug development with shareholder interests[14] - The company has implemented a restricted stock incentive plan in 2021, incurring share-based payment expenses of approximately RMB 7,689 thousand during the reporting period[79] - The company believes that the structured deposit agreements with banks will yield more favorable returns compared to traditional deposits[114] - The board of directors has approved the incentive plan to enhance the motivation and creativity of the employees involved[118] - The company has a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity and financial arrangements[94] - The company has no significant contingent liabilities or asset pledges as of December 31, 2022[86][87] Challenges and Risks - The company faced challenges in production and sales due to unexpected factors, impacting the normal operation of research and development projects[65] - The company faces risks related to new drug development, with a lengthy process that can take over ten years and significant uncertainty regarding the success of products in clinical trials[185] - The company’s product range is relatively narrow, with three main products contributing significantly to total revenue, which poses a risk if these products face competitive pressures or regulatory challenges[187] - Recent policies have led to a decline in drug prices, increasing competition and potential revenue impacts for the company, although its products are not currently subject to these price reductions[188] Dividend Policy - The company plans to distribute a final dividend of RMB 0.07 per share for the year ended December 31, 2022, totaling approximately RMB 72.03 million (including tax) based on 1,029,000,000 shares issued[197] - The proposed dividend distribution will be subject to approval at the annual general meeting scheduled for May 30, 2023[197] - The company has implemented a stable and proactive profit distribution policy since 2015, aiming for a cash dividend ratio of no less than 10% of the distributable profit in the first three years post-IPO[194] - The board of directors will consider the impact of cash dividends on the company's operational funding needs and any significant cash expenditures in the next twelve months[196]

Financial Performance - The company's revenue for the year ended December 31, 2022, was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[2] - Profit before tax for 2022 was RMB 132,294,000, down 38.7% from RMB 215,921,000 in the previous year[2] - The total comprehensive income attributable to shareholders for 2022 was RMB 136,847,000, a decline of 34.8% from RMB 210,016,000 in 2021[2] - The company's basic and diluted earnings per share for 2022 were RMB 0.1340, down from RMB 0.2049 in 2021, reflecting a decrease of 34.3%[2] - Net profit for 2022 was RMB 137,272,198, down from RMB 212,380,705 in 2021, representing a decline of 35.3%[13] - Total revenue for 2022 was $929.03 million, a decrease of 8.96% from $1,020.67 million in 2021[18] - Net profit for 2022 was $102.04 million, down 41.06% from $173.22 million in 2021[18] - Operating profit decreased to $105.92 million in 2022, compared to $177.03 million in 2021, reflecting a decline of 40.06%[18] Assets and Liabilities - The company's total assets as of December 31, 2022, amounted to RMB 2,976,007,000, an increase from RMB 2,781,172,000 in 2021[4] - Total liabilities increased to RMB 722,986,000 in 2022 from RMB 591,582,000 in 2021, representing a rise of 22.2%[4] - The company's total liabilities reached RMB 678,689,845 in 2022, an increase of 25.9% from RMB 539,099,929 in 2021[11] - Current liabilities rose to RMB 633,102,882 in 2022, compared to RMB 482,246,500 in 2021, an increase of 31.3%[11] - The company's total equity attributable to shareholders was RMB 2,257,102,000 as of December 31, 2022, compared to RMB 2,192,946,000 in 2021, showing an increase of 2.9%[8] Cash and Cash Equivalents - Cash and cash equivalents as of December 31, 2022, were RMB 1,289,302,664, up from RMB 1,208,880,911 in 2021[6] - Cash flow from operating activities for 2022 was $165.27 million, a decrease of 38.43% from $268.90 million in 2021[21] - The company reported cash and cash equivalents at year-end 2022 of $1.29 billion, an increase from $1.21 billion at the end of 2021[23] - Cash and bank deposits as of December 31, 2022, amount to RMB 1,289,258,185, an increase from RMB 1,208,855,545 in 2021[126] Research and Development - Research and development expenses increased slightly to RMB 226,850,903 in 2022 from RMB 224,387,287 in 2021, indicating a focus on innovation[13] - Research and development expenditures are classified into research phase and development phase, with development costs capitalized only if specific criteria are met[87] - Research and development expenses for 2022 totaled RMB 233,659,132, a decrease from RMB 248,153,842 in 2021, with RMB 226,850,903 recognized in profit or loss[178] Shareholder Equity and Dividends - The company distributed RMB 72,030,000 to shareholders in 2022, compared to RMB 52,150,000 in 2021, marking an increase of approximately 38.3%[34] - The total comprehensive income for 2022 was RMB 137,272,198, down from RMB 212,380,706 in 2021, reflecting a decrease of approximately 35.3%[34] - The company reported a total shareholder equity of RMB 2,321,921,130 as of December 31, 2022, reflecting a slight increase from the previous year[34] Inventory and Receivables - The company reported a decrease in inventory to RMB 40,526,760 in 2022 from RMB 35,625,222 in 2021, which is an increase of 13.4%[6] - The total accounts receivable balance as of December 31, 2022, is CNY 569,136,087, with an expected credit loss of CNY 14,777,342[138] - Accounts receivable as of December 31, 2022, total RMB 518,749,422, down from RMB 569,136,087 in 2021, indicating a decrease of approximately 8.8%[129] - The provision for bad debts for accounts receivable decreased to RMB 12,365,732 in 2022 from RMB 14,777,342 in 2021, reflecting a reduction of about 16.3%[133] Impairment and Provisions - The total impairment provision for assets decreased to CNY 16,229,937 from CNY 17,178,928 in 2021, reflecting a reduction of approximately 5.5%[190] - The provision for inventory write-down increased by CNY 3,052,947 during the year, resulting in a total of CNY 3,247,315 as of December 31, 2022, compared to CNY 4,771,622 in 2021[190] - The provision for bad debts for other receivables was zero as of December 31, 2022, compared to CNY (925) in 2021[151] Employee Compensation - The total employee compensation payable decreased to CNY 27,761,585 in 2022 from CNY 36,493,188 in 2021, reflecting a decline of about 24.5%[197] - The provision for employee benefits, including social insurance, was CNY 2,280,771 as of December 31, 2022, compared to CNY 491,727 in 2021, indicating a significant increase in employee-related expenses[199] Accounting Policies - The financial statements for the year 2022 were approved by the board of directors on March 27, 2023[41] - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete information[44] - The accounting year runs from January 1 to December 31, aligning with the calendar year[45] Other Financial Information - The company has adopted new accounting standards and interpretations issued by the Ministry of Finance, which had no significant impact on the financial statements[120] - The corporate income tax rate applicable to the company for the year 2022 is 15%, consistent with 2021[122] - The company has not recognized any taxable income for its subsidiary Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. for the years 2021 and 2022, resulting in no income tax expense[123]

Financial Performance - The company's operating revenue for Q3 2022 was RMB 445,006,305, representing a year-on-year increase of 2.60%[6] - The net profit attributable to shareholders for Q3 2022 was RMB 72,798,391, a decrease of 68.95% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was RMB 67,906,975, down 78.12% year-on-year[6] - The basic earnings per share for Q3 2022 was RMB 0.07, a decrease of 63.64% compared to the previous year[9] - Total operating revenue for the first three quarters of 2022 reached 716,265,980, an increase from 698,113,963 in the same period of 2021, representing a growth of approximately 2.3%[33] - Net profit for the first three quarters of 2022 was 36,739,951, down from 117,926,892 in 2021, indicating a decline of approximately 68.9%[36] - Total comprehensive income for the first three quarters of 2022 was 35,535,491, down from 116,165,685 in 2021, indicating a decrease of approximately 69.5%[39] Research and Development - The total R&D investment for Q3 2022 was RMB 71,029,256, accounting for 15.96% of operating revenue, a decrease of 7.70 percentage points year-on-year[9] - Research and development expenses rose to 171,893,365 in 2022 compared to 159,207,486 in 2021, marking an increase of about 8.5%[33] - The company’s development expenditures increased to CNY 33,998,236 from CNY 28,017,508, reflecting a growth of approximately 21.4%[28] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was RMB 196,182,795, an increase of 33.40% compared to the previous year[6] - Cash flow from operating activities for the first three quarters of 2022 was 196,182,795, an increase from 147,058,878 in 2021, showing a growth of approximately 33.5%[42] - Total cash inflow from investment activities was $2,860,270,307, an increase from $2,462,681,721[45] - Net cash flow from investment activities was -$79,977,072, an improvement from -$535,542,863[45] - The net increase in cash and cash equivalents was $28,262,995, compared to a decrease of $477,392,996 in the previous period[45] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,908,473,496, an increase of 4.58% from the end of the previous year[9] - As of September 30, 2022, the total assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. amounted to CNY 2,908,473,496, an increase from CNY 2,781,172,268 at the end of 2021, representing a growth of approximately 4.6%[25] - The total liabilities increased to CNY 695,635,874 from CNY 591,582,298, reflecting a rise of approximately 17.6%[30] - The company's total current assets reached CNY 1,995,022,020, up from CNY 1,927,945,778 in the previous year, indicating an increase of about 3.5%[25] - The total equity attributable to shareholders was CNY 2,216,277,478, up from CNY 2,192,945,932, indicating a growth of approximately 1.1%[30] Shareholder Information - The company has a total of 21,351 common shareholders at the end of the reporting period, with the top ten shareholders holding a combined 67.74% of shares[16] - The number of shareholders totaled 21,351, with 21,211 holding A shares and 140 holding H shares, indicating a diverse shareholder base[20] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 3.35%, an increase of 0.76 percentage points year-on-year[9] - The company reported a significant recovery in production and sales due to the control of the Shanghai pandemic, leading to a 48.79% increase in operating revenue for the current period[12] - The company experienced a significant increase in credit impairment losses, which amounted to -22,666,224 in 2022 compared to -4,431,214 in 2021[36] - Other income decreased to 2,481,052 in 2022 from 3,922,985 in 2021, reflecting a decline of approximately 36.7%[33] - Cash paid for dividends, profits, or interest was $72,030,000, an increase from $52,150,000[45] - The company has adopted new accounting standards starting from 2022, which may affect financial reporting[45]

[Financial Summary and Performance Highlights](index=2&type=section&id=Financial%20Summary%20and%20Performance%20Highlights) The company reported significant Q3 2022 revenue and net profit growth, though year-to-date net profit declined sharply due to increased share-based payment expenses [Key Financial Data](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E8%B2%A1%E5%8B%99%E6%95%B8%E6%93%9A) In Q3 2022, the company achieved significant year-on-year growth in operating revenue and net profit, while year-to-date net profit saw a substantial decline, influenced by increased share-based payment expenses | Item | Current Period (Q3 2022) (RMB Yuan) | YoY Change (%) in Current Period | Year-to-Date (First Three Quarters) (RMB Yuan) | YoY Change (%) Year-to-Date | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 445,006,305 | 48.79% | 716,265,980 | 2.60% | | **Net Profit Attributable to Shareholders of the Listed Company** | 72,798,391 | 37.02% | 36,823,845 | -68.95% | | **Net Profit Attributable to Shareholders of the Listed Company (Excluding Non-Recurring Gains/Losses)** | 67,906,975 | 43.50% | 22,288,451 | -78.12% | | **Basic Earnings Per Share (RMB/share)** | 0.07 | 40.00% | 0.04 | -63.64% | | **Total R&D Investment** | 71,029,256 | 0.37% | 177,874,093 | -0.22% | | **R&D Investment as % of Operating Revenue (%)** | 15.96% | Decreased by 7.70 percentage points | 24.83% | Decreased by 0.71 percentage points | | Item | End of Current Period (RMB Yuan) | End of Previous Year (RMB Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | **Total Assets** | 2,908,473,496 | 2,781,172,268 | 4.58% | | **Total Equity Attributable to Shareholders of the Listed Company** | 2,216,277,478 | 2,192,945,932 | 1.06% | [Non-Recurring Gains and Losses](index=3&type=section&id=%E9%9D%9E%E7%B6%93%E5%B8%B8%E6%80%A7%E6%90%8D%E7%9B%8A%E9%A0%85%E7%9B%AE%E5%92%8C%E9%87%91%E9%A1%8D) In the first three quarters of 2022, the company recorded total non-recurring gains of approximately RMB 14.54 million, primarily from structured deposit interest and government grants | Item | Amount Year-to-Date (RMB Yuan) | Description | | :--- | :--- | :--- | | Fair Value Changes and Investment Income from Financial Assets | 14,026,034 | Primarily interest from the Group's structured deposits | | Government Grants Recognized in Current Profit/Loss | 2,481,052 | / | | Gains/Losses on Disposal of Non-Current Assets | 1,381,059 | / | | Other Non-Operating Income and Expenses | -787,646 | / | | **Total** | **14,535,394** | / | [Analysis of Changes in Key Financial Indicators](index=3&type=section&id=%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E8%B3%87%E6%96%99%E3%80%81%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99%E7%99%BC%E7%94%9F%E8%AE%8A%E5%8B%95%E7%9A%84%E6%83%85%E6%B3%81%E3%80%81%E5%8E%9F%E5%9B%A0) Q3 revenue and profit growth were driven by post-epidemic recovery, while year-to-date net profit decline was primarily due to increased share-based payment expenses, and operating cash flow improved from extended payment cycles - Operating revenue and related profit indicators in the current reporting period (Q3) significantly increased year-on-year, primarily due to the recovery of drug production and sales after the Shanghai epidemic was brought under control[5](index=5&type=chunk) - Year-to-date, net profit attributable to parent company decreased by **68.95%** year-on-year, and non-recurring net profit attributable to parent company decreased by **78.12%**, mainly due to share-based payment expenses of **RMB 68.4417 million**, compared to **RMB 23.7992 million** in the same period last year[5](index=5&type=chunk) - Year-to-date, net cash flow from operating activities increased by **33.40%** year-on-year, primarily due to extended payment cycles for accounts payable[5](index=5&type=chunk) [Shareholder Information](index=4&type=section&id=%E8%82%A1%E6%9D%B1%E4%BF%A1%E6%81%AF) As of the reporting period end, the company had 21,351 common shareholders, with the top five shareholders holding over 70% of shares [Shareholder Profile and Top Ten Shareholders](index=4&type=section&id=%E8%82%A1%E6%9D%B1%E6%A6%82%E6%B3%81%E8%88%87%E5%89%8D%E5%8D%81%E5%A4%A7%E8%82%A1%E6%9D%B1) As of the reporting period end, the company had 21,351 common shareholders, with a concentrated equity structure where the top five shareholders collectively held over 70% of shares - As of the end of the current reporting period, the company had a total of **21,351** common shareholders, including **21,211** A-share holders and **140** H-share holders[6](index=6&type=chunk) | Shareholder Name | Shareholding (%) | Number of Shares Held | | :--- | :--- | :--- | | HKSCC NOMINEES LIMITED | 21.79 | 224,234,900 | | Shanghai Pharmaceuticals Holding Co., Ltd. | 20.42 | 210,142,560 | | Xinqi Phase II Venture Capital Enterprise | 15.25 | 156,892,912 | | Yang Zongmeng | 7.77 | 80,000,000 | | Wang Haibo | 5.63 | 57,886,430 | [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) The company's total assets increased by 4.58% to RMB 2.91 billion, while total liabilities rose by 17.59% to RMB 695.64 million, and net profit attributable to parent company declined by 68.95% year-to-date [Consolidated Balance Sheet](index=6&type=section&id=%E5%90%88%E4%BD%B5%E8%B3%87%E7%94%A2%E8%B2%A0%E5%82%B5%E8%A1%A8) As of September 30, 2022, total assets reached RMB 2.91 billion, increasing by 4.58% driven by construction in progress, while total liabilities grew by 17.59% due to higher other payables | Item | September 30, 2022 (RMB Yuan) | December 31, 2021 (RMB Yuan) | Change | | :--- | :--- | :--- | :--- | | **Total Assets** | **2,908,473,496** | **2,781,172,268** | **+4.58%** | | Cash and Cash Equivalents | 1,237,143,906 | 1,208,880,911 | +2.34% | | Construction in Progress | 112,124,690 | 48,899,044 | +129.29% | | **Total Liabilities** | **695,635,874** | **591,582,298** | **+17.59%** | | Other Payables | 577,314,935 | 443,978,184 | +30.03% | | **Total Equity Attributable to Parent Company Owners** | **2,216,277,478** | **2,192,945,932** | **+1.06%** | [Consolidated Income Statement](index=8&type=section&id=%E5%90%88%E4%BD%B5%E5%88%A9%E6%BD%A4%E8%A1%A8) In the first three quarters of 2022, total operating revenue slightly increased by 2.6%, but rising operating costs led to a 73.46% decline in operating profit and a 68.95% drop in net profit attributable to parent company | Item | First Three Quarters of 2022 (RMB Yuan) | First Three Quarters of 2021 (RMB Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | **Total Operating Revenue** | **716,265,980** | **698,113,963** | **+2.60%** | | **Total Operating Costs** | **667,789,596** | **592,930,829** | **+12.62%** | | Of which: Selling Expenses | 383,823,070 | 346,570,728 | +10.75% | | Administrative Expenses | 55,061,168 | 38,043,903 | +44.73% | | R&D Expenses | 171,893,365 | 159,207,486 | +8.00% | | **Operating Profit** | **30,756,721** | **115,898,651** | **-73.46%** | | **Net Profit Attributable to Parent Company Shareholders** | **36,823,845** | **118,614,270** | **-68.95%** | | **Basic and Diluted Earnings Per Share (RMB/share)** | **0.04** | **0.11** | **-63.64%** | [Consolidated Cash Flow Statement](index=9&type=section&id=%E5%90%88%E4%BD%B5%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In the first three quarters of 2022, net cash flow from operating activities increased by 33.40% to RMB 196.18 million, while net cash outflow from investing activities significantly narrowed | Item | First Three Quarters of 2022 (RMB Yuan) | First Three Quarters of 2021 (RMB Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | **196,182,795** | **147,058,878** | **+33.40%** | | **Net Cash Flow from Investing Activities** | **-79,977,072** | **-535,542,863** | Not Applicable | | **Net Cash Flow from Financing Activities** | **-88,302,716** | **-88,889,372** | Not Applicable | | **Net Increase in Cash and Cash Equivalents** | **28,262,995** | **-477,392,996** | Not Applicable | | **Cash and Cash Equivalents at Period End** | **1,237,143,906** | **919,497,196** | **+34.55%** | [Other Important Information](index=5&type=section&id=Other%20Important%20Information) The company reported no other significant operational information requiring investor attention, and the quarterly report was approved by the Board of Directors on October 27, 2022 [Other Important Reminders](index=5&type=section&id=%E5%85%B6%E4%BB%96%E6%8F%90%E9%86%92%E4%BA%8B%E9%A0%85) The company has no other significant information regarding its operations that requires investor attention during the current reporting period - The company has no other significant information regarding its operations that requires investor attention during the current reporting period[7](index=7&type=chunk) [Board of Directors Information](index=10&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E4%BF%A1%E6%81%AF) The quarterly report was approved by the Board of Directors on October 27, 2022, with a detailed list of executive, non-executive, and independent non-executive directors - These financial statements were approved for issuance by the Company's Board of Directors on **October 27, 2022**[13](index=13&type=chunk) - Board members include Executive Directors Wang Haibo, Su Yong, Zhao Dajun; Non-Executive Directors Shen Bo, Yu Xiaoyang; and Independent Non-Executive Directors Zhou Zhonghui, Lin Yaojian, Xu Qing, Yang Chunbao[14](index=14&type=chunk)

第四科江 FUDAN-ZHANGJIANG 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * (於中華人民共和國註冊成立的股份有限公司) ( 股票號碼：1349) 載 至 二 零 二 二 年 六 月 三 十 日 止 六 個 月 中 期 報 告 * 僅供識別 公司主要財務指標 一、公司主要會計數據和財務指標 （一）五年財務摘要 | --- | --- | --- | --- | --- | --- | |---------------------------------------------|-------------------------------------------|-------------------------|-------------------------|-----------------------------------------------|-----------------------| | | | | | | | | 業績 | | | 未經審核 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders for the same period was RMB 300 million, up 20% compared to the previous year[1]. - The company's operating revenue for the first half of the year was ¥271,259,675, a decrease of 32.02% compared to ¥399,037,102 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was -¥35,974,546, representing a decline of 154.94% from ¥65,485,448 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥45,618,524, a decrease of 183.64% compared to ¥54,543,664 last year[24]. - The net cash flow from operating activities was ¥59,366,826, an increase of 5.95% from ¥56,033,635 in the same period last year[24]. - The company's total assets at the end of the reporting period were ¥2,701,939,784, down 2.85% from ¥2,781,172,268 at the end of the previous year[24]. - The company's net assets attributable to shareholders at the end of the reporting period were ¥2,126,038,966, a decrease of 3.05% from ¥2,192,945,932 at the end of the previous year[24]. - The basic earnings per share for the reporting period was -¥0.03, a decline of 150.00% from ¥0.06 in the same period last year[24]. - The company achieved revenue of 271 million yuan during the reporting period, a year-on-year decrease of 32.02%[81]. - The net loss for the six months ended June 30, 2022, was RMB 36,020,882, compared to a profit of RMB 65,069,479 for the same period in 2021[185]. - The company reported a gross loss of RMB 60,771,766 for the six months ended June 30, 2022, compared to a profit of RMB 68,518,791 for the same period in 2021[185]. Research and Development - The R&D investment as a percentage of operating revenue increased to 39.39%, up 12.45 percentage points from 26.94% in the previous year[24]. - The company is conducting Phase I clinical trials for the FDA022 antibody-drug conjugate, targeting HER2-positive advanced solid tumors, with significant market potential[56]. - The company is conducting Phase II clinical studies for the use of Ammonium Ketone Acid in treating HPV-related cervical precancerous lesions and moderate to severe acne, with preclinical studies for gliomas completed[50]. - The company has established a gene engineering technology platform, focusing on the development of cytokine, fusion protein, monoclonal antibody, and antibody-drug conjugate products, with plans to enhance clinical research and registration for gene drugs[44]. - The company is exploring the development of PEGylated liposomal formulations to reduce cardiac toxicity associated with traditional treatments[37]. - The company is currently developing innovative drugs targeting skin diseases, tumors, and precancerous lesions, as well as antibody-drug conjugates for tumors[90]. - The company has a total of 147 patent applications, with 6 new applications in the current period, maintaining a strong intellectual property portfolio[57]. - Research and development expenses for the six months ended June 30, 2022, were RMB 102,559,780, an increase from RMB 98,267,565 in the same period of 2021[185]. - The company has achieved breakthroughs in the large-scale production process of its paclitaxel albumin nanoparticle project, indicating strong potential for market expansion[52]. Market Strategy and Outlook - The company has outlined a future outlook projecting a revenue growth of 10-15% for the second half of 2022[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[1]. - The company aims to address the unmet medical needs in the treatment of skin diseases and improve patient outcomes through innovative therapies[29]. - The company is exploring new sales models leveraging online academic exchange platforms to address common marketing challenges and improve patient access[76]. - The company plans to develop a new drug for Parkinson's disease in collaboration with Shanghai Handu Pharmaceutical, which is currently in Phase II clinical trials[93]. Operational Challenges and Risks - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faced operational challenges due to strict COVID-19 measures in Shanghai, impacting production and delivery schedules[24]. - The company faces risks related to the single variety of its products, as the main products are significantly impacted by competition and regulatory changes[86]. - The company is exposed to risks from potential price reductions in pharmaceuticals due to government policies and market competition[89]. Environmental and Compliance - The company has established a five-year environmental goal based on 2020 as the baseline year, focusing on emissions, waste, energy, and water resources to continuously improve environmental management levels[124]. - The company strictly adheres to national and local standards for pollutant emissions, including wastewater, waste gas, greenhouse gases, and waste, with no violations reported during the reporting period[123]. - The company has implemented a comprehensive energy performance management system, setting energy-saving targets for each department based on historical data and production realities[124]. - The company has established an emergency response mechanism for environmental incidents related to emissions, ensuring compliance with environmental protection regulations[123]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[123]. Shareholder and Governance - The company does not have a controlling shareholder, which may lead to governance instability and decision-making inefficiencies[85]. - The company committed to not transferring or entrusting its shares for 36 months post-IPO, with an extension of at least 6 months if the stock price falls below the issue price for 20 consecutive trading days within the first 6 months[130]. - The company will ensure compliance with legal requirements for related party transactions and maintain independence in operations and financial matters[130]. - The company will limit share reductions to no more than 5% of total shares outstanding per year for 2 years after the lock-up period expires[131]. - The company will ensure that any share sales will not be below the IPO issue price, with adjustments made for any corporate actions affecting share value[133].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產 生或因依賴該等內容而引致的任何損失承擔任何責任。 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* 二零二二年第一季度報告 上海復旦張江生物醫藥股份有限公司（「本公司」，聯同其附屬公司，「本集團」）之董 事會（「董事會」）欣然宣佈本公司及其附屬公司截至二零二二年三月三十一日止第一季 度（「本報告期」）期間按照中國企業會計準則編製的未經審計財務資料（「第一季度報 告」）。本公告乃根據香港法例第 571 章證券及期貨條例第 XIVA 部項下內幕消息條文及 香港聯合交易所有限公司證券上市規則第 13.09(2)和第 13.10B 條的要求作出。 1 / 9 主要財務數據 | --- | --- | --- | --- | |-----------------------------------------------|---------- ...

复旦我江 FUDAN-ZHANGJIANG 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) (股票號碼：1349) " 僅供歲別 年報 2021 目錄 頁碼 | --- | |--------------------| | | | 公司資料 | | 五年財務摘要 | | 主席報告 | | 管理層的討論及分析 | | 董事會報告 | | 監事會報告 | | 審核委員會報告 | | 薪酬委員會報告 | | 提名委員會報告 | | 戰略委員會報告 | | 獨立非執行董事報告 | | | 2 4 6 20 33 63 66 69 71 73 75 企業管治報告 77 | --- | --- | |-------|----------------------------| | | | | | 董事、監事及高級管理層簡介 | | | 環境、社會及管治報告 | | | 獨立核數師報告 | | | 合併財務報表 | | • | 合併資產負債表 | | • | ...